Hormonal treatment for prostate cancer

Expert Opinion on Investigational Drugs

Volumn 10, Issue 3, 2001, Pages 493-510

  Harris, K A ^a   Small, E J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hormone therapy; Prostate cancer

Indexed keywords

ABARELIX; ACID PHOSPHATASE; ALBUMIN; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; CORTICOTROPIN; DIETHYLSTILBESTROL; DRUG METABOLITE; ESTROGEN; ESTROGEN DERIVATIVE; FLUTAMIDE; FOLLITROPIN; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TESTOSTERONE DERIVATIVE; UNINDEXED DRUG;

ADVANCED CANCER; ANDROGEN SYNTHESIS; ANTINEOPLASTIC ACTIVITY; BONE PAIN; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CASTRATION; CONTROLLED STUDY; COST CONTROL; DIARRHEA; DRUG EFFICACY; DRUG RESEARCH; GYNECOMASTIA; HEALTH CARE COST; HORMONAL REGULATION; HORMONE INHIBITION; HOT FLUSH; HUMAN; IMPOTENCE; LIVER TOXICITY; MALE; MORBIDITY; PROSTATE CANCER; RECURRENT CANCER; REVIEW; TESTIS FUNCTION; THROMBOEMBOLISM; TREATMENT PLANNING; TUMOR REGRESSION; VISUAL DISORDER;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 0035114339     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.3.493     Document Type: Review

References (150)

1. Cancer statistics 2000
2. Carcinoma of the prostate
3. The question of castration for enlarged prostate
4. The present position of the surgery of the hypertrophied prostate
5. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
6. Studies on prostatic carcinoma: II. The effect of castration on advanced carcinoma of the prostate gland
7. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
8. Combined androgen blockade for the treatment of metastatic carcinoma of the prostate
9. The androgens
10. Activation of programmed cell death in the rat ventral prostate after castration
11. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies
12. Treatment and survival of patients with cancer of the prostate
13. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate
14. A Phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer
15. On the existence and separation of the follicle stimulating hormone releasing hormone from the luteinizing hormone releasing hormone
16. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: An approach toward the development of a male contraceptive
17. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer
18. 2 prostatic cancer patients
19. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma
20. Comparison of LH-RH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma
21. Advanced prostate cancer: What's new in hormonal manipulation?
22. Luteinizing hormone-releasing hormone agonists in prostate cancer
23. A randomised trial comparing the safety and efficacy of the zoladex 10.8 mg depot, administered every 12 weeks to that of the zoladex 3.6 mg depot, administered every 4 weeks, in patients with advanced prostate cancer
24. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogues in the treatment of metastatic carcinoma of the prostate
25. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist
26. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostate carcinoma by administration of an antiandrogen (nilutamide)
27. The magnitude of lupron (L) or zoladex (Z) testosterone (T) and luteinizing hormone (LH) surge is dependent on formulation: Comparative results of L and Z vs. abarelix-depot (A-D), a GnRH antagonist devoid of androgen surge
28. Abarelix-depot (A-D), a sustained-release (SR) formulation of a potent GnRH pure antagonist in patients (pts) with prostate cancer (PrCA): Phase II clinical results and endocrine comparison with superagonists lupron zoladex (Z)
29. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project
30. Current clinical studies with a new nonsteroidal antiandrogen, casodex
31. Effectiveness of antiandrogens in the rat
32. Fatal and nonfatal hepatotoxicity associated with flutamide
33. Flutamide hepatotoxicity
34. Casodex: A pure non-steroidal antiandrogen used as monotherapy in advanced prostate cancer
35. Absence of hepatic enzyme induction in prostate cancer patients receiving 'Casodex' (bicalutamide)
36. Maximal androgen blockade for patients with metastatic prostate cancer: Outcome of a controlled trial of bicalutamide (Casodex) versus flutamide, each in combination with luteinizing hormone releasing hormone analogue therapy
37. A randomized controlled clinical trial of leuprolide and Anandron versus leuprolide and placebo for advanced prostate cancer
38. Anandron (RU 23908) in metastatic prostate cancer: Preliminary results of a multicentric Italian study
39. Comparison of flutamide (SCH-13521) and diethylstil-bestrol in untreated advanced prostatic cancer
40. Experience with flutamide in previously untreated patients with advanced prostatic cancer
41. 2 prostate carcinoma: Flutamide versus diethyl-stilbestrol
42. Single-agent therapy with bicalutamide: A comparison with medical or surgical castration in the treatment of advanced prostate carcinoma
43. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer
44. A randomised comparison of 'Casodex" (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer
45. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: Results from two multicenter randomized trials at a median follow-up of 4 years
46. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease
47. Bicalutamide monotherapy versus flutamide pls goserelin in prostate cancer patients: Results of an Italian prostate cancer project study
48. High-dose bicalutamide for androgen-independent prostate cancer: Effect of prior hormonal therapy
49. Cardiovascular side effects of diethylstilbestrol, cyproteerone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Treatment of Cancer trials 30761 and 30762
50. Use of cyproterone acetate in prostate cancer
51. Treatment of advanced cancer of the prostate with megestrol acetate
52. Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma
53. Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer
54. Medical castration using megestrol acetate and minidose estrogen
55. Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate
56. Bilateral adrenalectomy in prostatic cancer
57. Antiandrogens in the treatment of prostatic cancer
58. New hormonal therapy in prostatic carcinoma: Combined treatment with an LH-RH agonist and an antiandrogen
59. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
60. Goserelin acetate and flutamide versus bilateral orchiectomy: A Phase III EORTC trial (30853)
61. Orchiectomy and nilutamide or placebo as treatment of metastatic prostate cancer in a multi-center double-blind randomized trial
62. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
63. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment
64. Efficacy of the combination of nilutamide and orchiectomy in patients with metastatic prostate cancer
65. Maximum androgen blockade with nilutamide combined with orchidectomy in advanced prostate cancer: An updated metaanalysis of 7 randomized, placebo-controlled trials (1191 patients)
66. Maximal androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients
67. Anti-androgens in treatment of prostate cancer
68. Anti-androgens in treatment of prostate cancer
69. Anti-androgens in treatment of prostate cancer
70. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials
71. Hormonal control of growth and progression in tumors of Nb rats and a theory of action
72. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
73. Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate specific antigen
74. Intermittent endocrine therapy for advanced prostate cancer
75. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer
76. Impact of intermittent androgen deprivation on quality of life (QOL)
77. Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS)
78. A pilot study of intermittent androgen deprivation in advanced prostate cancer
79. Intermittent androgen deprivation for clinically localized prostate cancer: Initial experience
80. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer
81. Finasteride
82. Finasteride, an inhibitor of 5-alpha reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia
83. Evidence for atrophy and apoptosis in the prostates of men given finasteride
84. The effect of finasteride in men with benign prostatic hyperplasia
85. Response of rat and human prostatic cancers to the novel 5-alpha reductase inhibitor, SK&F 105657
86. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer
87. Treatment with finasteride following radical prostatectomy for prostate cancer
88. Sequential adrogen blockade: A biological study in the inhibition of prostatic growth
89. Combined finasteride and flutamide therapy in men with advanced prostate cancer
90. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate
91. Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side effects
92. Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed
93. Intermittent androgen deprivation in prostate cancer patients: Factors predictive of prolonged time off therapy
94. Effect of glycyrrhetinic acid on DNA damage and unscheduled DNA synthesis induced by benzo(alpha)pyrene
95. Inhibition of tumor angiogenesis and metastasis by saponin of Panax ginseng, ginsenoside-Rb2
96. Antitumor active polysaccharides from the Chinese mushroom songshan lingzhi, the fruiting body of Ganoderma tsugae
97. Complete amino acid sequence of an immumodulatory protein, ling Zhi-8: An immunomodulator from a fungus, Ganoderma lucidum, having similarity to immunoglobulin variable regions
98. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives
99. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES
100. PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo
101. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer
102. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer
103. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease
104. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
105. Secondary hormonal manipulations in hormone refractory prostate cancer
106. Prostate specific antigen decline after antiandrogen withdrawal
107. Prostate-specific antigen decline after Casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome
108. Antiandrogen withdrawal syndrome with nilutamide
109. Antiandrogen withdrawal syndrome with nilutamide
110. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome
111. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate
112. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbesterol
113. Bicalutamide for advanced prostate cancer: The natural history versus treated history of disease
114. Nilutamide response after flutamide failure in postorchiectomy progressive prostate cancer
115. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of 'hormone-refractory' prostate cancer
116. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer
117. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: Simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal
118. Ketoconazole therapy for hormonally refractive metastatic prostate cancer
119. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
120. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma
121. Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
122. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliave end points
123. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
124. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma
125. A Phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate
126. Phase II study of megestrol acetate for metastatic carcinoma of the prostate
127. Megestrol acetate (MA) in men with hormone-refractory prostate cancer (HRPC): Prostate specific antigen (PSA) response and antiandrogen withdrawal (AAWD): Cancer and Leukemia Group B (CALGB) 9181
128. Megestrol acetate in the treatment of hormone refractory prostate cancer
129. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormonal blockade
130. Osteoporosis after orchiectomy for prostate cancer
131. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostate cancer
132. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy
133. Flutamide therapy for advanced prostatic cancer: A Phase II study
134. Flutamide as primary treatment for metastatic prostatic cancer
135. Flutamide versus stilboestrol in the management of advanced prostatic cancer: A controlled prospective study
136. Long-term experience with flutamide in patients with prostatic carcinoma
137. Flutamide monotherapy as primary treatment in advanced prostatic carcinoma
138. Update of monotherapy trials with the new anti-androgen casodex (ICI 176,334)
139. Bicalutamide in the treatment of advanced prostatic carcinoma: A Phase II noncomparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy
140. Total androgen ablation: Canadian experience
141. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer
142. First report of Australian multicenter randomized prostate cancer trial: Flutamide does not add to the effect of orchiectomy for metastatic prostate cancer
143. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer
144. A Phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate
145. Long-term results of Danish prostatic cancer group trial 86: Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer
146. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
147. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer
148. Intermittent androgen suppression for prostate cancer: Rationale and clinical experience
149. Current status of intermittent androgen suppression in the treatment of prostate cancer
150. Intermittent androgen suppression in the management of prostate cancer